#PRESSRELEASE We are proud to announce that PEMP is underway! Our observational clinical study on 500 women will look to understand the mechanisms at play in endometriosis and add more granularity to the disease. Amongst the women suffering from the disease, why do some improve with surgery, whilst others don’t? Is endometriosis truly one disease? Is one main process driving most of the cases? These are some of the questions our scientists hope to answer. Run in collaboration with Cambridge University Hospitals NHS Foundation Trust (study lead) and North West Anglia NHS Foundation Trust, we will deeply characterise the endometrium, lesions, blood and menstrual blood of women with and without endometriosis and link this to their clinical status and one-year outcomes. Read the full press release on our website and stay tuned for more updates!
Cyclana Bio
Biotechnology Research
A tissue-level multidisciplinary approach to curing Endometriosis.
About us
Our mission is to cure endometriosis. We are a team of interdisciplinary scientists creating a new model in women's health research centred around an in depth understanding of tissue-level disease processes. We are committed to improving the quality of life of women by providing a new model for therapeutic discovery. We sit at the interface between tissue biology, computation and laboratory disease modelling.
- Website
-
https://www.cycletherapeutics.org
External link for Cyclana Bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Cambridge
- Type
- Privately Held
Locations
-
Primary
Get directions
Cambridge, GB
Employees at Cyclana Bio
Updates
-
As breakthroughs start shaping more and more clinical care for women, it's important for us to build under a common language, share findings and work together to address the hurdles that we will all be facing to make these breakthroughs accessible to patients. We are excited to be a part of the Milken Institute's Women's Health Network, where we can start building together!
We are pleased to announce that the Milken Institute's Women’s Health Network, a global collaborative working to accelerate progress in women’s health, is now 170 member organizations strong! The newest members reflect the initiative's growing global reach, with 63 percent of joining organizations headquartered outside the United States, spanning diverse regions worldwide. Please join us in welcoming the following organizations to the Women's Health Network. 🔹 Absco Therapeutics 🔹 Amsterdam UMC 🔹 BoobyBiome 🔹 Brigham and Women's Hospital, Mary Horrigan Connors Center for Women's Health Research 🔹 CC Diagnostics 🔹 Cyclana Bio 🔹 decipHER women 🔹 Ema - AI for Women's Health 🔹 FemTech Across the Caribbean 🔹 Femtech Canada 🔹 Femtech France 🔹 Femtech Spain 🔹 FemTech Weekend 🔹 Florida Breast Cancer Foundation 🔹 Flourish Care 🔹 Gynaia 🔹 Hertility 🔹 i-Expand 🔹 May Health 🔹 NAVREF 🔹 Newcastle University 🔹 Office of the California Surgeon General 🔹 ŌURA 🔹 Pendulum Therapeutics 🔹 Proximie 🔹 Seen Health 🔹 SimpliFed 🔹 SPRIND - Bundesagentur für Sprunginnovationen 🔹 SteelSky Ventures 🔹 The Endometriosis Collective, Inc 🔹 University of Pennsylvania Perelman School of Medicine 🔹 Wellbeing of Women 🔹 Women's Health Hub Finland To learn more about the Women’s Health Network, visit thewomenshealthnetwork.org #MIWomensHealthNetwork #WomensHealth
-
-
We are very proud of our Founding Scientist Andrew Miller, PhD and the work he did alongside a group of great scientists before joining us! This work is a great example of why it is so important when treating a disease to reverse the extracellular and mechanical features of tissue level disease. Just like cells have mechanical memory, ECM also has memory and it can be very long, as seen in fibrosis. The ECM memory is contained in its composition, structure and cross-links, and it reinforces the mechanical memory in cells, which in turn reinforces the ECM. We believe that we need to reprogram ECM to wipe out the memory of disease, to make better reversing therapies and to make existing cellular therapies work more efficaciously. Really happy we were able to recruit Drew to our team to continue on this journey.
Tom Barker beat me to it first but incredibly excited to share that our most recent manuscript was published today in Advanced Science! In this work my incredible co-author Fereshteh Sadat Younesi and I extend the idea of mechanical memory conceptualized by Boris Hinz's group back in 2017 to compliant extracellular matrix. Here we married multi-omics with molecular biology approaches to identify and interrogate a novel transcriptional network headlined by the balance of the transcription factors SALL1 and GATA6 that serves to maintain pro-regenerative phenotypes in mesenchymal stromal cells. We find that SALL1 expression is restricted to culture in a soft microenvironment and serves as a negative regulator of pro-fibrotic gene activity. Additionally, SALL1 acts as a repressor of transcription factor GATA6 expression which we identify as a core mediator of maintaining stiffness-induced myofibroblast memory even after transitioning cells to soft, myofibroblast-resistant ECM. Bittersweet that the publication of this manuscript officially marks the end of my graduate career and time in Tom's lab at UVA but grateful for all of the influential lessons learned along the way! Endlessly appreciative of the opportunity to work with this collaborative team and all of the amazing work done by Fereshteh and our additional co-authors. An additional thank you to Boris and Tom for taking a chance on a naive graduate student's somewhat crazy idea to help crack this ridiculously cool code of mechanical adaptation and memory. Thankful (and a tad relieved) that all of that sequencing bore fruit in the end! 😅 😁 https://lnkd.in/ghP9U_bq
-
Very excited about this work published today in Science and co-led by our CSO Kevin Chalut, showing the importance of extracellular matrix in tissue function! This work makes us think differently about how chronic inflammatory diseases like endometriosis are driven: we believe the ECM is central to the pathology and can truly act in the causal pathway. Can we fix endometriosis and other diseases by changing the ECM? This paper inspires us to believe we can. We are working tirelessly in the lab to import these concepts into our assays, informed by our tissue-level data collection, to develop better drugs to help patients. Stay tuned for more! 🧪 🔬 https://lnkd.in/evA65Mmy
-
And just like that our team has grown again! We are absolutely thrilled to welcome two incredible scientists within our ranks to help translate our insights into tangible solutions for women with endometriosis. Helen Harrison has joined us as our Director of Discovery and Translational Biology. Her years of experience across modalities and indications make her the perfect person to help us revolutionise the therapeutic field of women's health! Andrew Miller, PhD has joined us as a Founding Scientist, at the interface of computational and experimental biology. His deep stromal and mechanobiology expertise have gotten him diving right into the lab already. Welcome to our mission both, let the breakthroughs continue!
-
-
#21toWatch - We were delighted and honoured to be recognised as one of seven companies in East of England driving forward much needed change (along with our great Babraham Research Campus neighbour Kourosh Sam Kamali)! What started off as a desire to shine a light on women's health, has grown so quickly into a larger but just as driven and passionate team, working daily on the basic biology that drives diseases like endometriosis. Thanks to our CSO Kevin Chalut for delivering a perfect 60s pitch, to the sponsors, judges and partners of this great event and to Innovate Cambridge for welcoming us at the Glasshouse. So you heard it from Faye Holland first, watch this space... 👀
-
-
We're thrilled to announce that Jonathan Griffiths has joined Cyclana Bio as Chief Technology Officer (CTO), where he'll be leading our computational efforts to advance women's health research. Jonny brings an unusually interdisciplinary background, with deep expertise spanning biology, functional genomics, human genetics, and machine learning—skills he combines to solve complex problems at their intersection. Previously, Jonny led machine learning teams at Altos Labs developing large language models for epigenetics, identified novel therapeutic targets for SLE at Genomics plc, and pioneered early analyses of large-scale single-cell RNA-sequencing data during his PhD in John Marioni's lab at the CRUK Cambridge Institute. We're excited to have Jonny's expertise as we work to transform our understanding of endometriosis and related conditions through innovative biomarker discovery. Welcome to the team, Jonny! 🥼 💻
-
-
Celebrating this year's science and the foundations that we have laid, for next year to bring us even closer to groundbreaking therapies in women's health. And with that, we are welcoming Siiri Salomaa to our ranks as a Founding Scientist! This title reflects how central of a role the team we are building today has in driving our mission forward. We're so excited to have you on board Siiri and to benefit from your wealth of experience in the field of mechanobiology. Wishing all of those who are following our journey Happy Holidays and a great 2026 from the Cyclana Team (filled with many more uterus-shaped gingerbread biscuits, courtesy of Louise Shanahan...).
-
-
Staying embedded within the academic sphere and discovery science is someone we believe in strongly and it’s always great to have our CSO and Co-Founder Kevin engage with the academic community!
I had a great time at the Laboratory for Medical Sciences at Imperial College earlier this week, doing one of my favourite things - talking about ECM and its essential role in building and maintaining tissue. I don't know how many times I have given such seminars or talks as an academic, sharing with people why I think ECM and tissue repair are such exciting, inextricably linked topics. But in this case, it was an especially interesting day, because it was the same day that we announced our raise at Cyclana Bio. This made it very real to me, really hit me that for right now (and who knows about the future) I am thinking about that science differently, and maybe even less as an academic. So here we are, Léa Wenger and I have been talking for a while about how there's a really important vector towards new targets, particularly for women's health, centred on matrix and tissue biology. Endometriosis, which has personal meaning for both of us, is our indication of choice. We are going to be sharing some papers and other developments here as we go. I will never lose my faith in the power of the discovery-based science I have grown up with - it is the engine of innovation. This hit home even further at Imperial, with such great discussions with amazing scientists around cell and tissue biology. I truly believe it's possible to work within the discovery and innovation mindset to bring new therapies to market that will revolutionise human health.
-